ResearchSafety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age
ResearchConcomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis
ResearchImpact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial
ResearchEfficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
ResearchThe Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
ResearchIncreasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD
ResearchIleal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability
ResearchMinor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease
ResearchRestorative Surgery for Ulcerative Colitis in the Elderly: An Analysis of Ileal Pouch-Anal Anastomosis Procedures from the American College of Surgeons National Surgical Quality Improvement Program
ResearchPatients with More Severe IBD Get Clostridioides difficile Rather than Clostridioides difficile Increasing the Severity of IBD
ResearchDisability in Inflammatory Bowel Disease Patients Is Associated With Race, Ethnicity and Socio-Economic Factors
ResearchEscalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile
ResearchAcute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases